Most healing peptide guides stop at BPC-157 and TB-500. That covers one bottleneck — tissue repair signaling — while ignoring the others: chronic inflammation that never resolves, mitochondrial energy failure in damaged cells, poor collagen remodeling, disrupted sleep, and hormonal timing that doesn't support overnight recovery.
The three-tier framework here organizes eleven compounds by function — a core stack everyone starts with, situational additions matched to specific injury types, and support compounds that optimize the recovery environment. The goal isn't a longer ingredient list. It's a diagnostic approach: identify what's actually stalling your healing, then address that bottleneck specifically.
| At a Glance | |
|---|---|
| Core stack | BPC-157 + TB-500 + KPV + NAD+ — addresses perfusion, inflammation, and cellular energy. |
| Injury-specific | GHK-Cu (connective tissue), VIP (disc/spine), ARA-290 (nerve pain) — matched to your injury type. |
| Support layers | SS-31 (stalled healing), Selank (stress), DSIP (sleep), Tesamorelin/Sermorelin (GH recovery) — added if needed. |
| Protocol duration | 4–8 weeks for acute injuries, 8–12 weeks for chronic conditions. |
| Results timeline | Reduced pain and improved mobility within 1–2 weeks, structural remodeling at 4–8 weeks, full protocol effects by 8–12 weeks. |
| Key caveat | All multi-peptide protocols are practitioner-derived. No human RCTs exist for any combination. Individual compounds have preclinical support; stacking rationale is mechanistic, not clinical. |
The evidence landscape is uneven. BPC-157 has 36 studies in a 2025 systematic review — 35 preclinical, 1 clinical with 12 patients.¹ TB-500 has roughly 50 preclinical studies and no human trials. Zero human RCTs exist for any multi-peptide combination. Every stacking protocol described here is practitioner-derived, built on mechanistic rationale and clinical observation rather than controlled trials.
BPC-157 is on the FDA Category 2 list (cannot be compounded) and is WADA prohibited. TB-500 is also WADA prohibited. These classifications reflect compounding enforcement actions, not safety findings from adverse event data.
Why Injuries Stall: Six Bottlenecks
An injury that doesn't improve after 4–6 weeks isn't just "slow healing." Something specific is blocking the repair process. Six failure points account for most stalled recoveries.
1. Poor perfusion — the tissue is starved
Damaged tissue needs blood flow to deliver oxygen, nutrients, and immune cells. When circulation is restricted — common in tendons, ligaments, and avascular joint surfaces — repair stalls at the earliest stage.
Signs: the area stays cold or pale, swelling persists weeks post-injury, improvements from physical therapy don't hold between sessions. BPC-157 signals new blood vessel formation (angiogenesis¹), and TB-500 mobilizes repair cells and coordinates their migration to the injury.²
2. Chronic inflammation — the cleanup crew won't leave
Acute inflammation is necessary — it clears debris and initiates repair. But when the inflammation switch stays on and inflammatory molecules keep circulating (NF-kB signaling³), the tissue stays in a destructive loop instead of transitioning to rebuilding.
Signs: persistent warmth, redness, or swelling beyond 2–3 weeks; pain that worsens with rest rather than activity; morning stiffness that doesn't improve. KPV turns off the inflammation switch directly (NF-kB blockade³), calming inflammation without suppressing the repair signals that NSAIDs and corticosteroids impair.
3. Cellular energy failure — repair cells can't do the work
Tissue repair is metabolically expensive. Repair cells, immune cells, and blood vessel cells all require functional mitochondria producing adequate energy. In damaged tissue, mitochondria are often compromised by oxidative stress.
Signs: healing that starts but plateaus; recurrent setbacks with modest activity; fatigue concentrated around the injury site. NAD+ restores cellular energy, and SS-31 stabilizes mitochondrial membranes under stress.⁴
4. Poor collagen quality — rebuilding with weak material
New tissue forms, but it lacks structural integrity. Collagen fibers are disorganized, cross-linking is insufficient, and the repair tissue doesn't tolerate load. Common in connective tissue injuries where collagen architecture determines function.
Signs: repeated re-injury at the same site, tissue that feels "loose" or unstable, gains that reverse under load. GHK-Cu regulates collagen remodeling enzymes, directing repair toward organized functional tissue rather than scar.⁵
5. Poor sleep quality — the repair window never opens
Growth hormone peaks during deep sleep, driving overnight tissue repair. When sleep architecture is disrupted — fragmented sleep, insufficient deep sleep stages, or difficulty falling asleep during recovery — the body's primary repair window stays closed.
Signs: waking unrefreshed, difficulty reaching or maintaining deep sleep, recovery that stalls despite good daytime compliance with rehab and nutrition. DSIP restores deep sleep architecture directly. Selank addresses the stress and anxiety that fragment sleep in the first place.
6. Hormonal mis-timing — recovery signals fire at the wrong time
Even with adequate sleep, growth hormone release can be blunted — cortisol stays elevated through the night, GH pulses are weak or mistimed, and the overnight repair signal never reaches full amplitude.
Signs: slow healing despite decent sleep, compounding fatigue that doesn't match activity level, poor recovery response to rehab. GH secretagogues like tesamorelin or sermorelin restore pulsatile GH release.⁶
These bottlenecks frequently overlap. A tendon injury with poor blood supply (1) often develops chronic inflammation (2) because inadequate circulation prevents immune cell clearance. The core stack covers the three most common bottlenecks, with situational and support additions for the rest.
The Peptide Toolkit: Building Your Protocol
Step 1 — Start with the Core Stack
Everyone starts here. These four compounds cover perfusion, inflammation, and cellular energy — the three bottlenecks that stall most recoveries. The BPC-157 + TB-500 combination is the foundation of the Wolverine Stack, with KPV and NAD+ extending coverage.
| Compound | Role |
|---|---|
| BPC-157 | Drives repair at the injury site — builds new blood vessels, activates the cells that lay down new tissue, and upregulates growth hormone receptors locally.¹ |
| TB-500 | Mobilizes repair cells to the injury and coordinates how they organize — functional tissue instead of scar. Reduces fibrosis. Combined with BPC-157, contractile function restored earlier than either alone.⁷ |
| KPV | Turns off the inflammation switch (NF-kB³) that BPC-157's secondary effects don't fully cover. Chronic inflammation is the most common reason injury healing plateaus. |
| NAD+ | Supplies the cellular energy every repair process runs on. Damaged tissue has compromised mitochondria — NAD+ keeps the energy pipeline open so the other compounds can do their work. |
Oral alternative to BPC-157
PDA — same 15-amino-acid sequence, stabilized with an arginate salt for oral bioavailability.⁸ PDA at 500–1000 mcg/day replaces injectable BPC-157 for readers who want to avoid injections. Trade-off: oral delivery is systemic rather than local, so you lose concentrated signaling near the injury site.
Step 2 — Match Your Injury Type
After establishing the core, add the compound that targets your specific injury:
| Injury Type | Add | Rationale |
|---|---|---|
| Connective tissue / collagen quality | GHK-Cu | Regulates collagen turnover enzymes — directs repair toward organized functional tissue instead of scar. Add when tissue feels unstable or you keep re-injuring the same site.⁵ |
| Disc / spinal degeneration | VIP | Only peptide with direct disc data — slowed degeneration and improved disc cushioning material in a mouse model.⁹ Short half-life (~1 min IV), so frequent dosing matters. |
| Nerve pain / neuropathy | ARA-290 | Activates the innate repair receptor — reduced pain and regenerated small nerve fibers in Phase 2 human trials.¹⁰ Systemic injection, doesn't need to be near the nerve. |
Step 3 — Add Support If Needed
These address bottlenecks that emerge during recovery, not upfront:
| Signal | Add | Why |
|---|---|---|
| Healing stalled after 4+ weeks on core | SS-31 | Stabilizes mitochondrial membranes against oxidative damage that accumulates during prolonged repair.⁴ |
| High stress during recovery | Selank | Reduces anxiety with immune-modulating properties. Breaks the stress → cortisol → impaired healing cycle without sedation. |
| Poor sleep quality | DSIP | Restores deep sleep architecture — the phase where GH-driven repair happens. |
| Weak GH response / slow overnight recovery | Tesamorelin or Sermorelin | Restores pulsatile GH release. Complementary to DSIP — DSIP opens the window, secretagogues amplify the signal. Before bed, empty stomach. Cycle 8–12 weeks on, 4 weeks off. |
For cartilage-specific interest, Cartalax is a Russian bioregulator with lab-based cartilage-protective data but no injury recovery evidence.
Protocol: Dosing, Timing, and Schedules
Core Stack
| Compound | Dose | Route | Timing |
|---|---|---|---|
| BPC-157 | 250–500 mcg | SubQ near injury site | Daily |
| TB-500 | 2.5 mg (loading) → 1.25 mg (maintenance) | SubQ near injury site | 2×/week (weeks 1–4), then 1×/week |
| KPV | 200–500 mcg | SubQ near injury site | Daily |
| NAD+ | 100–250 mg | IM | Daily |
Inject near the injury site — within 1–2 cm when possible. BPC-157, TB-500, and KPV are chemically compatible and can be drawn into the same syringe. On TB-500 days, all three go in one injection. On other days, BPC-157 + KPV in one injection. NAD+ is a separate IM injection. For injuries in hard-to-reach locations (spine, deep hip), abdominal injection is the practical option for all compounds.
TB-500 loading phase
The loading phase (2.5 mg 2×/week for 4 weeks) establishes tissue saturation; maintenance (1.25 mg weekly) sustains it.¹¹ Microdosing TB-500 is ineffective — unlike BPC-157, which operates on a signaling-threshold model where even small doses trigger the repair cascade.
If planning on using TB-500, verify it's not mislabeled TB-4. True TB-500 is the 7-amino-acid active fragment (~800 Da) specifically engineered for tissue repair. TB-4 is the full 43-amino-acid parent molecule (~4,900 Da). Both work, but the fragment benefits more from local injection — it concentrates the active region at the injury site. Check the Certificate of Analysis: molecular weight tells you which you have. See the TB-500 guide for details.
Calculate your exact injection volumes with the peptide dosing calculator.
Situational Compounds
| Compound | Dose | Route | Timing | Injury Type |
|---|---|---|---|---|
| GHK-Cu | 1–2 mg | SubQ | Daily | Connective tissue, collagen quality |
| VIP | 100–200 mcg | SubQ | Daily (can split into 2 doses) | Disc, spinal degeneration |
| ARA-290 | 2–4 mg | SubQ, abdomen | Daily | Nerve pain, neuropathy |
GHK-Cu can be added to the same injection as BPC-157 and KPV. ARA-290 is injected systemically — its nerve-protective effects don't require proximity to the nerve injury.¹⁰ VIP's ~1-minute half-life means subQ dosing provides brief systemic exposure; splitting the daily dose into two injections extends coverage.
Optional Support Compounds
| Compound | Dose | Route | Timing |
|---|---|---|---|
| SS-31 | 5–10 mg | SubQ | Daily (loading), then 2–3×/week |
| Selank | 250–500 mcg | SubQ or intranasal | Morning or before rehab |
| DSIP | 100–300 mcg | SubQ | Before bed |
| Tesamorelin | 1–2 mg | SubQ | Before bed, empty stomach |
| Sermorelin | 200–500 mcg | SubQ | Before bed, empty stomach |
SS-31
Targets the mitochondria directly — it stabilizes the inner membrane that produces cellular energy (cardiolipin binding⁴). NAD+ provides the fuel; SS-31 protects the engine. Consider it when healing stalls after 4+ weeks on the core stack, suggesting mitochondrial exhaustion that NAD+ alone isn't resolving.⁴
Selank
Can be injected subQ or taken intranasally. Intranasal bypasses liver processing and provides more direct brain access, which may give it an edge for stress and anxiety specifically.
Sleep and GH recovery
DSIP and GH secretagogues (tesamorelin, sermorelin) work on related but distinct problems. DSIP extends the deep sleep window — the phase where GH-driven repair actually happens. Secretagogues amplify the GH signal within that window. They're complementary, not redundant. GH secretagogues are dosed before bed on an empty stomach (90+ minutes after eating) and cycled 8–12 weeks on, 4 weeks off.
Injury-Specific Protocol Adjustments
Tendon, Ligament, and Fascia
The strongest preclinical case for peptide-assisted healing. BPC-157 promotes tendon repair cell outgrowth and stimulates cell migration (FAK-paxillin signaling¹³). Rat Achilles tendon studies show accelerated healing with improved biomechanical strength.¹ TB-500-treated Achilles tendons showed uniform fiber bundles with increased collagen fibril diameter versus controls.¹⁴
Protocol
Core stack injected near the injury site. Add GHK-Cu if collagen quality is the bottleneck (tissue feels unstable, re-injury at the same site). Collagen peptide supplementation (5–15 g/day, 30–45 min before tendon-loading exercise) is a well-supported adjunct.¹⁵
Plantar fasciitis
No direct peptide data. Plantar fascia is structurally similar to tendon — dense type I collagen, minimal vascularity — and shares the same wear-and-tear degeneration pattern. Same mechanisms are biologically plausible but unvalidated for plantar fascia specifically.
Joint and Cartilage
Core stack plus GHK-Cu for collagen quality. A case series of 17 patients reported symptom reduction in over 90% following intra-articular BPC-157 injections for knee joint conditions.⁷
GH secretagogues and joint injuries: monitor carefully
GH can cause mild joint swelling as a side effect — in joints with existing inflammation, cartilage degradation, or impingement, that additional fluid and tissue growth can worsen symptoms rather than help. If you're adding tesamorelin or sermorelin for overnight recovery, watch for increased joint stiffness or swelling in the first 2 weeks. Discontinue if impingement worsens. Ligament-driven injuries tolerate GH secretagogues better than cartilage or joint surface injuries.
Worth tracking: a 2025 Stanford study showed that blocking the enzyme 15-PGDH in aged mice regenerated articular cartilage — increasing smooth-cartilage-producing cells from 22% to 42%.¹⁶ Small molecule approach, not a peptide, but the most rigorous cartilage regeneration advance in the field. Phase 1 safety trials are underway.
Shoulder and Rotator Cuff
Core stack. BPC-157 at 10 mcg/kg produced total functional recovery in a rat rotator cuff model — full range of motion restored.¹⁷
GH secretagogues for shoulder: negative results
The only human RCT testing GH on rotator cuff repair (Oh 2018, n=76) found no significant improvement.¹⁸ A separate preclinical study found GH actually worsened force-to-failure at the tendon-bone interface.¹⁸ If you're using GH secretagogues for general recovery, monitor for increased shoulder stiffness or impingement — the same joint swelling side effect applies here.
For frozen shoulder, relaxin-2 is mechanistically targeted — it reverses joint capsule scarring in mouse models — but remains preclinical.
Disc, Spine, and Back
Core stack. BPC-157 has the strongest animal data for spinal cord injury — a single injection in rats produced consistent motor recovery, resolved spasticity by day 15, and counteracted nerve fiber breakdown over 360 days.¹⁹ TB-500 reduced nerve cell loss and scar tissue formation in separate models.²⁰
For disc degeneration, add VIP — the only peptide with direct disc data.⁹ For neuropathic pain from nerve compression, add ARA-290.
No human RCTs exist for peptides in disc herniation or back pain. The spinal cord injury data involves severe acute trauma models — extrapolation to chronic disc degeneration is mechanistic, not validated. BPC-157 has not been directly tested on herniated discs in any model.
Post-Surgical Recovery
Core stack. Start 48–72 hours post-operatively to allow initial clotting and the acute inflammatory response to settle before introducing repair signaling. BPC-157 injected locally near the surgical site. Phase approach: loading weeks 1–4, maintenance weeks 5–8, extended remodeling weeks 9–12 for complex surgeries.¹¹
BPC-157 can counteract corticosteroid-impaired healing in preclinical models, suggesting compatibility with post-surgical steroid protocols.¹
Chronic and Old Injuries
Core stack plus GHK-Cu, with adjusted expectations. Chronic injuries have established scar tissue, adapted blood supply patterns, and often mitochondrial depletion. Timelines extend to 8–12 weeks versus 4–6 for acute injuries. Add SS-31 if the core stack produces initial improvement that plateaus.
Timeline: What to Expect
| Timeframe | What's Happening |
|---|---|
| Days 1–7 | BPC-157 initiates new blood vessel formation. Injury site may feel warmer as circulation returns. Inflammatory tone begins shifting with KPV. |
| Weeks 1–2 | Most people notice reduced pain and improved mobility. TB-500 loading phase establishes tissue saturation. |
| Weeks 2–4 | Active tissue remodeling. New collagen deposition begins. Range of motion and load tolerance improve. |
| Weeks 4–8 | Structural maturation. Collagen fibers organize under mechanical load. Physical therapy and progressive loading compound the peptide effects. |
| Weeks 8–12 | Full protocol effects for chronic injuries. Reassess at week 8 — if stalled, evaluate for collagen quality, sleep, or hormonal timing bottlenecks. |
Supporting Factors
Peptides provide biological repair signals. The raw materials for actual tissue construction come from nutrition and mechanical loading.
Collagen peptide supplementation
5–15 g/day, taken 30–45 minutes before tendon-loading exercise or physical therapy. Vitamin C (500–1000 mg, taken with collagen) is a required cofactor for collagen cross-linking. Glycine (3–5 g/day) provides the most abundant amino acid in collagen structure.¹⁵
Progressive mechanical loading
Non-negotiable. Collagen fibers align along lines of mechanical stress. Without controlled loading, new tissue forms as disorganized scar. Peptides and rehab are synergistic — neither replaces the other.
Sleep
GH secretion peaks during deep sleep. DSIP and GH secretagogues address this pharmacologically, but basic sleep hygiene remains the foundation.
FAQ
Protocol Basics
Do I need NAD+ for injury healing?
NAD+ isn't a healing compound — it's the energy currency that fuels every repair process in the protocol. Repair cells, immune cells, and blood vessel cells all require functional mitochondria producing adequate energy. In damaged tissue, mitochondrial function is often compromised by oxidative stress.
Injectable NAD+ (100–250 mg/day IM) keeps the metabolic pipeline open so BPC-157, TB-500, and KPV can execute their signaling. Oral precursors (NMN or NR, 250–500 mg/day) are an alternative if you want to avoid the additional injection. You can run the protocol without NAD+ entirely, but you're asking repair cells to work overtime on a depleted energy budget.
What if I only take BPC-157 — can I expect results?
Yes. BPC-157 alone has the strongest individual evidence base for tissue repair among the compounds in this protocol.¹ Many people start with BPC-157 alone and see meaningful improvement, particularly for localized injuries.
The full core stack addresses more bottlenecks simultaneously — TB-500 adds cell mobilization, KPV covers inflammation, NAD+ covers energy — but BPC-157 alone is a reasonable starting point for mild-to-moderate injuries where chronic inflammation isn't the primary issue.
What is the typical cycle length for a BPC-157 + TB-500 injury protocol?
4–8 weeks for acute injuries. 8–12 weeks for chronic conditions.
TB-500 requires a loading phase (2.5 mg 2×/week for the first 4 weeks) to establish tissue saturation, then drops to maintenance (1.25 mg weekly). BPC-157 runs daily throughout. Reassess at week 4 (acute) or week 8 (chronic). GH secretagogues cycle separately: 8–12 weeks on, 4 weeks off.
What if healing stalls after 4 weeks?
Reassess using the bottleneck framework. If the core stack addressed perfusion (1), inflammation (2), and energy (3), the remaining bottlenecks are collagen quality (4) — add GHK-Cu — poor sleep (5) — add DSIP — and hormonal timing (6) — add a GH secretagogue.
If none of the above applies, add SS-31 for mitochondrial membrane instability that NAD+ alone didn't resolve. Don't just extend the same protocol hoping for different results.
Which peptides are best for inflammation?
KPV is the standout. It turns off the inflammation switch (NF-kB³) without the tissue-weakening effects of corticosteroids or the repair-signal suppression of NSAIDs.
BPC-157 has secondary anti-inflammatory properties but isn't primarily an anti-inflammatory compound. For gut-related inflammation, oral KPV acts directly on intestinal tissue via a gut nutrient transporter (PepT1). For injury-specific inflammation, subcutaneous KPV near the injury site provides concentrated local effect.
What if this protocol doesn't work for my specific injury?
First, confirm you're addressing the right bottleneck. The most common reason protocols underperform isn't the wrong compounds — it's the wrong diagnosis of what's stalling healing.
Second, check the non-peptide fundamentals: progressive mechanical loading, collagen supplementation, sleep quality, nutrition. Their absence limits the protocol's effectiveness.
Third, if the core stack produced initial improvement that plateaued, that's a specific signal: consider SS-31 for mitochondrial support or GHK-Cu for collagen remodeling. If nothing has moved after 4 weeks with proper rehabilitation, consult a physician — the injury may require imaging or intervention that peptides can't replace.
Safety and Regulatory
Are any of these peptides FDA approved?
No. None of the peptides in this protocol have FDA approval for injury recovery.
BPC-157 is on the FDA Category 2 list (cannot be compounded). SS-31 (elamipretide) has been through Phase III trials for Barth syndrome but hasn't received approval. ARA-290 completed Phase 2 trials for sarcoidosis neuropathy but development stalled. TB-500 and KPV have no FDA regulatory action for or against.
The absence of FDA approval reflects patent economics. BPC-157 is a fragment of a naturally occurring gastric protein — it cannot be patented as a novel compound, which means no company can recoup the $1–2 billion cost of full approval. The same economic barrier applies to most peptides derived from endogenous human sequences. Regulatory status tells you about commercial viability, not about safety or efficacy.
Is BPC-157 safe? Is TB-500 safe? Are there side effects?
BPC-157: No acute toxicity across a wide dose range in 6-week animal studies.¹ Side effects are mild — occasional injection-site irritation, GI upset with oral dosing. No long-term studies beyond 6 weeks exist.
TB-500: Phase I human safety data — 54 healthy volunteers received IV doses with no serious adverse events.²⁵ The synthetic TB-500 sold by peptide suppliers differs from the recombinant version used in trials, and its safety profile has not been independently characterized.
KPV: Tripeptide fragment of alpha-MSH, a naturally occurring hormone. No adverse events in published research, but no formal human safety studies exist either.
Short-term data is reassuring but not comprehensive.
Do BPC-157 and TB-500 cause cancer?
No evidence of tumor promotion exists for either compound.
BPC-157's blood-vessel-forming properties raise a theoretical concern — tumors need blood supply, and a compound that promotes capillary formation could theoretically support that. However, preclinical data suggests BPC-157 may actually inhibit certain tumor growth pathways.²² TB-500 research has found both pro- and anti-tumorigenic associations in different tissue contexts.
Anyone with active cancer or recent cancer history should avoid blood-vessel-forming compounds as a precaution. For people without cancer history, the theoretical risk appears low, but long-term human studies that would definitively resolve this don't exist.
Can I take BPC-157, TB-500, and KPV with NSAIDs or ibuprofen?
You can, but it may blunt the protocol's effectiveness. NSAIDs suppress inflammatory signaling that BPC-157 and TB-500 modulate as part of the repair process. Suppressing inflammation pharmacologically while trying to support it with peptides creates competing signals.
KPV works differently — it turns off the inflammation switch (NF-kB) to resolve chronic inflammation without suppressing repair signals. Running KPV alongside NSAIDs is less contradictory, but redundant.
If you need pain management during the protocol, use NSAIDs sparingly at the lowest effective dose rather than daily. Corticosteroids present a stronger concern — they directly impair collagen quality.
What are the contraindications?
Active cancer or history of cancer — BPC-157's blood-vessel-forming properties are theoretically concerning for tumor blood supply. No evidence of tumor promotion exists, and preclinical data suggests BPC-157 may inhibit certain tumor growth pathways,²² but the theoretical concern warrants caution.
Pregnancy and lactation — insufficient safety data. Autoimmune conditions — immune-modulating peptides (KPV, TB-500, Selank) may alter immune balance unpredictably.
Pharmacokinetics
How long do BPC-157 and TB-500 remain in your system?
BPC-157 clears in approximately 15 minutes (IV/IM studies in rats and dogs — no formal human subQ data exists). But plasma clearance doesn't equal effect duration. BPC-157 triggers gene expression cascades that persist for weeks to months after the compound clears.¹⁹ The peptide delivers instructions; the biological response continues independently.
TB-500 has better human data: Phase I studies in 54 healthy volunteers showed a dose-dependent half-life of 0.5–2.1 hours after IV administration.²⁵ Caveat: these studies used recombinant human thymosin beta-4, not synthetic TB-500 via subQ — the pharmacokinetics may differ.
How long do KPV and VIP remain in your system?
KPV has no published half-life data in any species. As an unmodified tripeptide, it likely clears within minutes. Anti-inflammatory effects persist longer because the inflammation switch (NF-kB) stays off after the peptide clears.
VIP has well-established human pharmacokinetics: approximately 1-minute half-life after IV administration. SubQ absorption is slower than IV, which provides somewhat longer exposure per dose. Splitting the daily dose into two injections extends coverage further. The disc degeneration research used local delivery models, but community protocols use systemic subQ at 100–200 mcg/day.⁹
How long do NAD+ and SS-31 remain in your system?
Injectable NAD+ (subQ or IV) enters the metabolic pool directly. SubQ provides sustained elevation over several hours. Oral precursors (NMN, NR) are an alternative with lower bioavailability — plasma NR peaks around 3 hours after oral dosing.
SS-31 (elamipretide) has the best pharmacokinetic data of any compound in this protocol — Phase I through III human trials. SubQ: peak plasma in 1–2 hours, half-life approximately 4 hours. Unusually long for a peptide because SS-31 contains unnatural amino acids that resist enzymatic breakdown.
How long does ARA-290 remain in your system?
Approximately 20 minutes half-life after subQ injection (human data from multiple clinical trials). Despite the short plasma presence, biological effects persist far longer — activation of the innate repair receptor triggers downstream gene expression lasting hours. This is why dosing is once daily despite 20-minute clearance.¹⁰
Administration
Do I inject BPC-157, TB-500, and KPV near the injury site?
All three: near the injury site when possible. SubQ within 1–2 cm of the injury concentrates each compound where repair signaling is needed.¹ For injuries in difficult-to-reach locations (spine, deep hip), abdominal injection is the practical option.
BPC-157, TB-500, and KPV are chemically compatible — draw all three into the same syringe on TB-500 days. On non-TB-500 days, BPC-157 + KPV in one injection.
Where do I inject ARA-290? Where do I inject VIP?
ARA-290: subcutaneous, typically abdominal. The sarcoidosis neuropathy trials used systemic delivery, not local injection. Its neuroprotective effects don't require proximity to the nerve injury.¹⁰
VIP: subcutaneous, 100–200 mcg daily. The ~1-minute IV half-life is short, so splitting into two doses (morning and evening) extends coverage. SubQ absorption is slower than IV, which helps. The disc degeneration research used local delivery models, but community protocols use systemic subQ.
SS-31 is expensive — what role does it play and is it worth it?
SS-31 protects mitochondrial membranes. NAD+ provides the fuel; SS-31 protects the machinery that burns it.⁴
It's not a first-line compound. Consider it only if healing stalls after 4+ weeks on the core stack — that suggests mitochondrial exhaustion that NAD+ alone isn't resolving. For chronic injuries with long-standing tissue damage, the case is stronger from the start.
For a mild acute injury responding to the core stack, SS-31 is unnecessary. For a chronic injury that has resisted other interventions, it addresses a bottleneck that nothing else in the protocol targets.
Is there a difference between oral BPC-157 (PDA) and the injectable version?
Same 15-amino-acid sequence, different delivery. PDA stabilizes BPC-157 with an arginate salt for oral bioavailability.⁸ Injectable near the injury site concentrates the compound locally. Oral PDA distributes systemically — lower concentration at any specific site, broader coverage overall.
For localized injuries, injectable is preferred. For systemic inflammation, gut healing, or avoiding injections entirely, oral PDA at 500–1000 mcg/day is the alternative. Some practitioners use both.
Is there a difference between oral and injectable KPV?
Yes. Oral KPV reaches intestinal tissue directly via a gut nutrient transporter (PepT1) — specifically effective for gut inflammation. Injectable KPV (subQ) provides systemic anti-inflammatory coverage including at injury sites.
For this protocol, subcutaneous KPV is the default. Oral KPV is the better choice only if your recovery is complicated by concurrent GI inflammation.
Does it matter if I use a nasal spray or injection for Selank?
Both work. SubQ injection is the default in this protocol since you're already injecting. Intranasal bypasses liver processing and provides more direct brain access, which is where Selank's anxiety-reducing effects are most relevant — so intranasal may have an edge for stress and anxiety specifically.
Compatibility
Can I use this protocol alongside GLP-1 based weight-loss therapy?
No direct interaction data exists. They target entirely different receptor systems.
The practical concern is metabolic context. GLP-1 therapy produces significant caloric deficit and muscle mass reduction. Tissue repair is metabolically expensive. Running an aggressive recovery protocol during aggressive caloric restriction may limit healing capacity.
If you're on GLP-1 therapy during injury recovery: prioritize protein intake (1.6–2.2 g/kg/day minimum), collagen peptide supplementation, and ensure your caloric deficit isn't starving the repair process.
Can I use peptides alongside physical therapy?
Not only can you — you should. Peptides provide biological repair signals. Physical therapy provides mechanical loading signals. Collagen fibers align along lines of stress; without controlled loading, new tissue forms as disorganized scar.
The combination is synergistic — neither replaces the other. Time collagen peptide supplementation (5–15 g with vitamin C) 30–45 minutes before PT sessions.¹⁵
What additional benefits might I notice from this protocol?
The compounds don't limit their effects to one injury site. Practitioners commonly report improved skin quality, faster healing at unrelated sites, and reduced GI symptoms as secondary effects of BPC-157.¹ GHK-Cu improves skin elasticity and wound healing beyond the target injury.⁵ NAD+ has broad metabolic effects beyond the injury site.
These aren't bonus features to chase — they're natural consequences of the mechanisms being engaged.
Injury-Specific
What should I add for a tendon or ligament injury?
Core stack with BPC-157 injected locally. This is the strongest preclinical case: BPC-157 promotes tendon repair cell outgrowth,¹³ TB-500 increases collagen fibril diameter and fiber organization.¹⁴ Add GHK-Cu if tissue feels unstable or you're re-injuring at the same site. Supplement with collagen peptides 30–45 minutes before tendon-loading exercise.¹⁵
What about joint and cartilage injuries?
Core stack plus GHK-Cu for collagen quality. A 17-patient case series reported symptom reduction in over 90% following intra-articular BPC-157 for knee conditions.⁷ Cartilage is the hardest tissue to regenerate — set expectations for 8–12 weeks minimum.
GH secretagogues can cause mild joint swelling — monitor carefully if adding them alongside a joint injury. Discontinue if impingement or stiffness worsens. Ligament-driven injuries tolerate them better than cartilage or joint surface problems.
What should I add for a shoulder or rotator cuff injury?
Core stack. BPC-157 produced total functional recovery in a rat rotator cuff model.¹⁷
Be cautious with GH secretagogues. The only human RCT testing GH on rotator cuff repair (n=76) found no significant improvement, and a separate preclinical study found GH actually worsened tendon-bone interface strength.¹⁸ If using them for general recovery support, watch for increased shoulder stiffness or swelling.
What should I add for disc, spine, or back pain?
Core stack. BPC-157 has the strongest animal data for spinal cord injury — motor recovery, resolved spasticity, counteracted nerve fiber breakdown over 360 days.¹⁹ For disc degeneration, VIP is the only peptide with direct data.⁹ For nerve pain from compression, add ARA-290.¹⁰
No human RCTs exist for peptides in disc herniation or back pain. The evidence gap between animal spinal cord data and human disc pathology is real.
What about post-surgical recovery?
Core stack, started 48–72 hours post-op. BPC-157 injected locally near the surgical site. Loading weeks 1–4, maintenance weeks 5–8, extended remodeling weeks 9–12 for complex surgeries.¹¹
BPC-157 can counteract corticosteroid-impaired healing in preclinical models — relevant if your post-surgical protocol includes steroids.¹
What about chronic or old injuries?
Core stack plus GHK-Cu, with adjusted expectations. Timelines extend to 8–12 weeks. Chronic injuries have established scar tissue, adapted blood supply patterns, and often mitochondrial depletion.
Add SS-31 if the core stack produces initial improvement that plateaus. These injuries also respond more to progressive mechanical loading — the tissue needs to be reminded what functional loading patterns look like.
References
¹ Vasireddi N et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." HSS J. 2025 Jul. PMC12313605
² Sosne G et al. "Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts." FASEB J. 2010. PubMed 20536458
³ Dalmasso G et al. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology. 2008. PMC2431115 — KPV enters cells via PepT1 transporter and blocks NF-kB activation directly; anti-inflammatory without the tissue-weakening effects of corticosteroids.
⁴ Birk AV et al. "The mitochondria-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin." J Am Soc Nephrol. 2013. PMC3752943 — SS-31 (elamipretide) binds cardiolipin in the inner mitochondrial membrane, stabilizing electron transport and ATP production under stress.
⁵ Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." Int J Mol Sci. 2018. PMC6073405
⁶ Rahman OF, Lee SJ, Seeds WA. "Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions." J Am Acad Orthop Surg Glob Res Rev. 2026;10(1). PMC12753158
⁷ Rahman OF et al. 2026 — combined administration data, GHK-Cu orthopaedic exploration, GH secretagogue evidence, BPC-157 case series (n=17). PMC12753158
⁸ PDA retains the identical 15-amino-acid sequence as BPC-157, enhanced with arginate salt for increased acid stability and oral bioavailability. Rahman OF et al. 2026; ScienceDirect "Application of peptide therapy for ligaments and tendons." 2025.
⁹ Sun et al. "Sympathetic Neurotransmitter, VIP, Delays Intervertebral Disc Degeneration via FGF18/FGFR2." Advanced Science News, 2023/2024. Source
¹⁰ Heij L et al. "Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study." Mol Med. 2012. PMC3521784 — ARA-290 activates the innate repair receptor; neuroprotective and small-fiber regenerative without erythropoietic effects.
¹¹ Practitioner protocol architecture — TB-500 mass-action pharmacology, BPC-157 signaling-threshold model, phase-based dosing structure. wolverinepeptidestack.com protocols; Ben Greenfield "Ultimate Peptide Power Plays."
¹² SS-31 attenuated LPS-induced apoptosis and pyroptosis of nucleus pulposus cells via mitochondrial ROS scavenging. ScienceDirect 2024.
¹³ Chang et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011. PubMed 21030672
¹⁴ Sosne G et al. 2010 — thymosin beta-4 treated Achilles tendons showed uniform fiber bundles with increased collagen fibril diameters vs controls. PubMed 20536458
¹⁵ Kirmani BH et al. "The effects of collagen peptide supplementation on body composition, collagen synthesis, and recovery from joint injury and exercise: a systematic review." Amino Acids. 2021. PMC8521576 — and Kvist M et al. 2025 (collagen + explosive strength RCT). PubMed 40623147
¹⁶ Singla M, Wang YX et al. "Blocking a master regulator of aging regenerates joint cartilage in mice." Science, Nov 2025. Stanford News
¹⁷ Sikiric et al. "Effect of pentadecapeptide BPC 157 on rotator cuff tear injury in rat." FASEB J. 2014;28(S1):844.9. FASEB
¹⁸ Oh et al. "Effect of recombinant human growth hormone on rotator cuff healing after arthroscopic repair." Am J Sports Med. 2018. PubMed 29337026 — and Vaysman et al. "Pharmacologic Enhancement of Rotator Cuff Repair: A Narrative Review." PMC9441107
¹⁹ Jurjus et al. "BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats." J Appl Biomed. 2019. PubMed 31266512
²⁰ "Beneficial effects of thymosin beta4 on spinal cord injury in the rat." 2014. PubMed 24937047
²¹ Cushman CJ et al. "Local and Systemic Peptide Therapies for Soft Tissue Regeneration: A Narrative Review." Yale J Biol Med. 2024;97(3):399-413. PMC11426299
²² McGuire FP et al. "Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing." Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMC12446177
²³ Liao HJ, Chen HT, Chang CH. "Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis." Cartilage. 2024. PMC11556548
²⁴ Rudnik-Jansen et al. "Biomolecular therapies for chronic discogenic low back pain: A narrative review." 2024. PMC11303450
²⁵ Wang et al. "Phase I study of recombinant human thymosin β4." Ann Transl Med. 2021. PMC8419156
This content is for educational purposes only. Peptides discussed here are investigational compounds. Consult a physician before beginning any peptide protocol, particularly if you have active cancer, autoimmune conditions, or are taking medications that affect immune function or coagulation.
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.